Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2015. The report serves as a notification to the market regarding the Company's total voting rights and capital structure as of March 31, 2015, in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure and voting rights.
- Issued Share Capital: 5,357,328,743 Ordinary Shares of 25p each.
- Treasury Shares: 491,515,950 Ordinary Shares.
- Total Voting Rights: 4,865,812,793.
Material Changes
The filing text does not provide a clear value for material changes versus the prior comparable period. The document is a static notification of share capital status as of a specific date.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document contains no forward-looking statements or operational commentary.
Investor Verification Checklist
- Verify the total number of voting rights (4,865,812,793) for compliance with Financial Conduct Authority disclosure thresholds.
- Confirm the number of shares held in Treasury (491,515,950) to calculate the correct denominator for ownership percentage calculations.
- Note that this filing does not contain financial performance data; refer to Form 20-F or quarterly earnings releases for revenue and profit metrics.